CTLA-4-disrupted cytotoxic T lymphocytes exhibited a pronounced anti-tumor effect in vivo in the subcutaneous xenograft BC model [38], making a rationale for CTLA-4 targeting in clinical trials. The gene discussed is CTLA4; the disease is neoplasm.